BackEpizyme Overview

Epizyme Current Assets

Latest current assets for EPZM: $190M.

Get informed when a big investor buys or sells

+ Follow
Current Assets
$186.84M
↓ 31.43% YoYΔ $-85.65M vs prior year quarter

Peer average

Loading

Epizyme Current Assets History

Loading

Epizyme vs. peers: Current Assets Comparison

Loading

Epizyme Current Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Epizyme (EPZM) FAQ

As of the most recent data (June 2022), EPZM shows a current assets of $190M. That compares with $270M in the prior-year period — down 31.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, EPZM's current assets is now $190M (was $270M) — a 31.4% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Epizyme is outperforming or lagging.

Tracking EPZM's current assets over time shows whether Epizyme is scaling, shrinking, or reshaping that part of the business. The current reading is $190M That compares with $270M in the prior-year period — down 31.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current assets page, Stockcircle has Epizyme's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current assets (currently $190M) with ownership activity and broader fundamentals.

Epizyme's current assets is $190M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.